MWVC
SLXP

Morgens Waterfall Vintiadis & Co’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-29,500
Closed -$2.65M – 57
2013
Q4 		$2.65M Sell
29,500
-500
-2% -$39.9K 1.82% 23
2013
Q3 		$2.01M Buy
30,000
+15,000
+100% +$1.03M 1.47% 24
2013
Q2 		$992K Buy
+15,000
New +$858K 0.76% 37

Other funds holding SLXP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's SLXP Position: Q1 2014 in Review

Morgens Waterfall Vintiadis & Co sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2014, closing a stake of 29,500 shares — an estimated $2.65M sold.

Morgens Waterfall Vintiadis & Co first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $2.65M in Q4 2013. 304 funds tracked by Wall St. Rank hold SLXP as of Q1 2014.

  • Morgens Waterfall Vintiadis & Co reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2014 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 29,500 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2014, an estimated $2.65M.
  • Morgens Waterfall Vintiadis & Co first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Morgens Waterfall Vintiadis & Co's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.65M in Q4 2013.
  • 304 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2014.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2014, filed 8 May 2014.